April 16, 2014     Japanese 
  JCN 
	  Network - Home
JCN Newswire
  Home  |  Companies  | Annual Reports  |  CSR  | News Alerts     
 
Share:
ViroMed Obtains Clinical Trial Approval of Gene Therapy Treatment for Chronic Granulomatosis
 

Tokyo, Jan 11, 2007 (JCN) - Takara Bio affiliate ViroMed Co., Ltd., based in Korea, announced the Korea Food & Drug Administration approval of their clinical trial of VM106, gene therapy treatment drug, for chronic granulomatosis.

Takara Bio's RetroNectin method was used under license in the clinical trial.

For the Retro Nectin treatment, VM106 utilizes a retro virus vector to inject gp91, the normal treatment gene, into the extracted haematopoietic stem cell of the patient. Afterwards a sample of this is injected back into the patient.

By Aki Tsukioka Contributor

Copyright © 2014 JCN. All rights reserved. A division of Japan Corporate News Network KK.


 Company Profile |   Print  |   Alerts
ACN Newswire

 Recent  Takara Bio  News  
  Takara Bio Completes Enrollment for Phase I Clinical Trial in the US for HF10 Anti-Cancer Therapy  (Apr 10, 2014)
  Takara Bio to Distribute ZENOAQ's Cell Cryopreservation Medium in Japan, Europe, and North America  (July 26, 2013)
  Takara Bio launches Nippi's iMatrix-511 Worldwide  (July 12, 2013)
  Takara Bio Grants Cellular Dynamics a Commercial License to Use RetroNectin for iPSC Production  (June 24, 2013)
  Takara Bio Licenses Mushroom Production Technology to Sun Toward Tech  (June 13, 2013)
  Takara Bio Initiates Phase 1 HIV Gene Therapy Clinical Trial  (Jan 7, 2013)
  Takara Bio Submits IND Application for HIV-1 Gene Therapy to the FDA  (Mar 23, 2012)
  Takara Bio and Tianjin Medical University in Gene Therapy Project  (Aug 3, 2011)
  Takara Bio RetroNectin to UCLA for TCR-gene Therapy Clinical Trials in Advanced Melanoma  (Dec 18, 2008)
  Takara Bio Announces Start of Clinical Research of Cancer Immunotherapy using RetroNectin(R) Expansion Culture System at Tianjin Cancer Institute & Hospital, China  (May 2, 2008)



 Recent  Biotech News   
Takara Bio Completes Enrollment for Phase I Clinical Trial in the US for HF10 Anti-Cancer Therapy (Apr 10, 2014)
Dainippon Sumitomo Pharma Establishes Anti-Cancer Drugs Sales Company in the U.S. (Oct 10, 2013)
EIZO, Stryker to Partner in Monitor Management Systems for Operating Rooms (Oct 8, 2013)
HOYA to Invest in EndoMaster, for Robotic-assisted Surgical Systems (Aug 19, 2013)
Dainippon Screen Launches High-speed Three-dimensional Cell Culture Scanner (Aug 8, 2013)
Daiichi Sankyo Expands Collaborative Drug Discovery Program to Germany, Switzerland, and Austria (Aug 1, 2013)
Takara Bio to Distribute ZENOAQ's Cell Cryopreservation Medium in Japan, Europe, and North America (July 26, 2013)
Takara Bio launches Nippi's iMatrix-511 Worldwide (July 12, 2013)
Furukawa Electric Develops Quartz Dot Test Kit to Detect Acanthamoeba (July 10, 2013)
Takara Bio Grants Cellular Dynamics a Commercial License to Use RetroNectin for iPSC Production (June 24, 2013)

More Biotech news...

 Recent  Biotech News   
Takara Bio Completes Enrollment for Phase I Clinical Trial in the US for HF10 Anti-Cancer Therapy (Apr 10, 2014)
Dainippon Sumitomo Pharma Establishes Anti-Cancer Drugs Sales Company in the U.S. (Oct 10, 2013)
EIZO, Stryker to Partner in Monitor Management Systems for Operating Rooms (Oct 8, 2013)
HOYA to Invest in EndoMaster, for Robotic-assisted Surgical Systems (Aug 19, 2013)
Dainippon Screen Launches High-speed Three-dimensional Cell Culture Scanner (Aug 8, 2013)
Daiichi Sankyo Expands Collaborative Drug Discovery Program to Germany, Switzerland, and Austria (Aug 1, 2013)
Takara Bio to Distribute ZENOAQ's Cell Cryopreservation Medium in Japan, Europe, and North America (July 26, 2013)
Takara Bio launches Nippi's iMatrix-511 Worldwide (July 12, 2013)
Furukawa Electric Develops Quartz Dot Test Kit to Detect Acanthamoeba (July 10, 2013)
Takara Bio Grants Cellular Dynamics a Commercial License to Use RetroNectin for iPSC Production (June 24, 2013)

More Biotech news...
 
CSR Report Download
Annual Reports

  More >>    
Most Popular


About JCN | Privacy Policy | Terms of Use | JCN Network (日本語)